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Idiopathic pulmonary fibrosis is a progressive, irreversible, debilitating, and fatal lung disease, characterized by
parenchymal fibrosis with reduced lung volumes and respiratory failure. No lasting option for therapy is
available other than transplantation. Mesenchymal stem/stromal cells home to sites of injury, decrease
inflammation, have antifibrotic properties, and promote epithelial tissue repair, so their use has been suggested
as potential therapy for idiopathic pulmonary fibrosis. Despite reported benefits, the amount of mesenchymal
stromal cells engrafting to the lung decreases substantially soon after administration. New strategies, such as
hypoxia preconditioning, have thus been investigated in an attempt to optimize the engraftment, survival, and
paracrine properties of stem cells. Hypoxia induces the expression of prosurvival mediators, chemoattractants,
and growth factors involved in cell proliferation, migration, angiogenesis, antioxidant, antiapoptotic, and
antifibrotic properties in mesenchymal stromal cells, optimizing their lung repair capability in an animal model
of idiopathic pulmonary fibrosis.Introduction
Idiopathic pulmonary fibrosis (IPF) is a chronic, diffuse,
fibrotic disease of the lung parenchyma of unknown eti-
ology. Progressive deposition of collagen fibers in the
lung interstitium inevitably leads to fatigue, dyspnea,
hypoxia, and respiratory failure in patients with end-
stage IPF. Although current pharmacological and non-
pharmacological therapies can temporarily lessen the
severity of symptoms, no effective treatment for IPF has
been developed to rescue the impaired lung, prevent
lesion progression, or both. Lung transplantation is con-
sidered the only curative approach. However, the signifi-
cant shortage of suitable donor lungs and the many
complications related to post-transplantation immuno-
suppression mean there is a dire need for new thera-
peutic approaches. In this context, mesenchymal stem/
stromal cell (MSC)-based therapy is a promising alterna-
tive for the treatment of lung diseases. Novel strategies
to optimize the beneficial effects of cell therapy have* Correspondence: prmrocco@biof.ufrj.br
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survival, engraftment, and paracrine properties of MSCs.
In a recent issue of Stem Cell Research & Therapy,
Lan et al. [1] demonstrated that transplantation of
hypoxia-preconditioned MSCs exerted better thera-
peutic effects in a mouse model of bleomycin-induced
pulmonary fibrosis and enhanced the survival rate of
engrafted MSCs, partially due to upregulation of hep-
atocyte growth factor (HGF).Main text
Repair of fibrotic lung parenchyma remains a significant
clinical challenge. All currently available therapeutic
trials in IPF are severely limited due to the lack of a
clear understanding of the natural history of the dis-
ease. To date, treatment of IPF has been based on the
concept that inflammation leads to injury; thus, most
therapies have been based on eliminating or suppress-
ing the inflammatory component through administration
of anti-inflammatory agents including corticosteroids,
immunosuppressants/cytotoxic drugs (e.g., azathioprine,
cyclophosphamide), and anti-fibrotic agents (e.g., colchi-
cine or D-penicillamine), alone or in combination [2].ss article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
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based therapy has been proven unequivocally to alter or
reverse the fibrotic process.
MSC-based therapy is an attractive alternative approach
for the treatment of IPF, as MSCs home to sites of injury,
inhibit inflammation, and contribute to epithelial tissue
repair [3]. In addition, MSCs secrete paracrine mediators
with antiapoptotic, anti-inflammatory, and antifibrotic ef-
fects [3]. Álvarez et al. [4] showed that lung-engrafted
MSCs possessed the ability to ameliorate fibrotic effects
in mice challenged with bleomycin. However, despite
reported successes, the amount of engrafted MSCs de-
creased dramatically 1 day after transplantation due to
exposure to harsh, toxic, and oxidative microenviron-
ments [3]. New strategies to optimize cell therapy out-
comes are therefore being investigated. A recent study
involving overexpression of antioxidants, chemokine
receptors, antiapoptotic genes, prosurvival genes, or
growth factors in engrafted stem cells has shown im-
proved cell survival following transplantation [5].
Additionally, cells may be preconditioned by sublethal
exposure to selected stressors to induce prior expres-
sion of cytoprotective genes before subsequent lethal
challenges [6]. Cellular preconditioning may include
exposure of cells to physiological stimuli such as heat
shock, small-molecule pharmacological agents, cyto-
kines, growth factors, biophysical stimuli, or hypoxia
[7]. Choosing appropriate preconditioning strategies
may provide a simple yet effective way of promoting
survival, enhancing regenerative properties, and boost-
ing the tissue repair capability of transplanted cells in
stem cell-based therapy [8].
The main insight of Lan et al.’s study was the use of
hypoxic preconditioning (HP), which upregulated cyto-
protective and regenerative genes, stabilized mitochon-
drial membrane potentials, increased homing ability,
promoted cell proliferation, and acted against hydrogen
peroxide-induced cell death in the treated MSCs. More-
over, hypoxia-preconditioned mesenchymal stem/stromal
cells (HP-MSCs) attenuated bleomycin-induced cell apop-
tosis and extracellular matrix (ECM) production through
transforming growth factor (TGF)-β1-mediated Akt sig-
naling via paracrine effects. Lan et al. were the first to
show that engraftment of HP-MSCs had therapeutic ef-
fects superior to those of untreated MSCs in a model of
bleomycin-induced pulmonary fibrosis. Engafted HP-
MSCs improved lung function, reduced lung edema, and
reduced levels of proinflammatory and fibrotic factors.
HP and stem cell transplantation have been extensively
studied in a number of organs and tissues as a means of
enhancing therapeutic effects in diseases such as stroke,
myocardial infarction, traumatic brain injury, diabetes
mellitus, inflammatory bowel disease, and acute kidney
and liver injuries [7–9]. However, there have been nopublished studies on the use of HP-MSCs to treat pul-
monary fibrosis.
Furthermore, Lan et al. demonstrated that transplant-
ation of HP-MSCs attenuated ECM deposition, in a
mechanism attributed to upregulation of HGF in the fi-
brotic lung. In this process, HGF plays a key role in pre-
venting fibrosis or scar formation after injury, by inhibiting
TGF-β-mediated myofibroblast differentiation and ECM
production. HGF also exerts multiple protective effects
on injured tissues via mitogenic, antiapoptotic, anti-
inflammatory, and antifibrogenic signaling [10].
Conclusion
Lan et al. [1] suggest that hypoxia-preconditioned MSC
therapy enhanced the survival rate of engrafted MSCs,
exerted superior therapeutic effects, and improved lung
functions in bleomycin-induced pulmonary fibrosis in
mice. Further studies should be conducted to ascertain
whether HP-MSCs have similar beneficial effects in other
models of fibrosis.
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